On November 19, 2024, [Anand Mehra](https://www.gurufocus.com/insider/29172/anand-mehra), a Director at Aclaris Therapeutics Inc, purchased 666,666 shares of the company, according to the [SEC Filing](http://www.sec.gov/Archives/edgar/data/1557746/000141588924027348/xslF345X01/form4-11202024_041101.xml). Following this transaction, the insider now owns a total of 710,030 shares in Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc (ACRS, Financial) is a biopharmaceutical company focused on developing therapies to address significant unmet needs in dermatology and immunology. The company is engaged in the research and development of novel drug candidates.
The insider transaction history for Aclaris Therapeutics Inc indicates a trend of insider buying, with 8 insider purchases and 0 insider sales over the past year. This trend is illustrated in the image below.
On the day of the recent purchase by Anand Mehra, shares of Aclaris Therapeutics Inc were trading at $2.25 each, resulting in a [market cap](https://www.gurufocus.com/term/mktcap/ACRS) of $282.866 million. The [GF Value](https://www.gurufocus.com/term/gf-value/ACRS) of the stock is estimated at $5.40, giving it a price-to-GF-Value ratio of 0.42. This suggests that the stock is modestly undervalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as the [price-earnings ratio](https://www.gurufocus.com/term/pe-ratio/ACRS), [price-sales ratio](https://www.gurufocus.com/term/ps-ratio/ACRS), [price-book ratio](https://www.gurufocus.com/term/pb-ratio/ACRS), and [price-to-free cash flow](https://www.gurufocus.com/term/price-to-free-cash-flow/ACRS). It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, along with future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
